Podcasts about GLP

Is the new Iran deal a historic mistake, and is modern America repeating the fatal errors of Ancient Rome? Ben Domenech breaks down current foreign policy shifts with legendary historian Victor Davis Hanson. In this edition of The Big Ben Show, Ben unpacks his major reservations regarding the proposed Iran memorandum of understanding (MOU) and what it reveals about American strength. Joined by Victor Davis Hanson, senior fellow at the Hoover Institution, they dive deep into the administration's foreign policy strategy, the reality of regional military threats, and whether modern America is tracking the cultural, fiscal, and border-related collapse of the Western Roman Empire. Later in the episode, culinary icon Christopher Kimball joins the show to celebrate America's 250th anniversary through our unique food traditions. Kimball shares budget-friendly cooking strategies to combat inflation, grilling secrets for your summer celebrations, and explores how GLP-1 lifestyle shifts are fundamentally altering American palates. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Spencer Nadolsky and Karl bring on Dr. Austin Baraki and Dr. Jordan Feigenbaum from the Barbell Medicine crew for a conversation that cuts through one of the most hyped and least understood topics in the health and fitness space right now: the research peptides that millions of people are injecting into themselves based on anecdotes, social media marketing, and the logic that short chain amino acids are natural so they must be fine. In this episode they cover what peptides actually are from a basic biochemistry standpoint and why calling something a short chain amino acids does not make it a food or a supplement it makes it a drug with all the same questions around safety efficacy dosing and long-term effects that any other drug requires, why the explosion of GLP-1 popularity essentially normalized both injectable medications and the idea that if semaglutide works this well what else is out there leading directly to the current peptide boom, why BPC-157 has no randomized controlled trial data in humans and the three human trials that were started were all terminated early with results never published which is a red flag that would make people furious if it were a vaccine but barely registers in the peptide space, why TB-500 has wound healing data when applied topically but nothing when injected despite being universally marketed as a muscle and tendon healer, why MOTS-C has never been tested in humans at all and yet enormous numbers of people are currently injecting it, why the argument that big pharma would sell these if they worked is actually the correct argument and why most of these compounds were abandoned precisely because they failed in trials or showed harm signals, why biological plausibility is a dangerous standard to rely on given that suppressing arrhythmias seemed biologically obvious until the CAST trial showed it killed people and beta blockers for heart failure seemed obviously wrong until trials showed they were life saving, what a randomized controlled trial actually does that anecdote cannot and why thousands of positive experiences are not equivalent to controlled data, why a JAMA study on SARMs sold as research chemicals found that only 18 of 44 products actually contained what was on the label meaning people may not even be getting the compound they think they are getting, why the doctors on this podcast could have made millions of dollars branding and selling their own peptide lines and have specifically chosen not to, and what standard of evidence they believe should be the minimum before recommending any compound to another human being. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Only roughly 50% of new GLP-1 prescriptions were getting approved for coverage in 2023. From a plan sponsor's seat, that looks like pharmacy trend spiking 9%, 12%, even 20% year over year. From a pharma manufacturer's seat, it's half their prescriptions not getting filled. Same market, opposite problems — and that's exactly the lens this episode flips on. In this episode, Stacey Richter speaks with Ophelia Johnson, who built new business channels for a pharmaceutical manufacturer that created the GLP-1 boom and has since launched a consulting practice at e-fi.works, about how cash pay models work from the inside — coupon platforms, telehealth channels, white label pharmacy models, and employer carve-outs — and where the new fees are hiding. WHAT YOU'LL LEARN ✅ How the Inflation Reduction Act, PBM legal scrutiny, drug shortages, and the compounding bypass converged with ~50% GLP-1 prior auth denial rates in 2023 to push pharma into building cash pay channels that cut the PBM out entirely ✅ How the savings coupon model works: manufacturer buys the patient down to a flat transparent cash price via platforms like GoodRx, pays a fixed per-script fee instead of a PBM rebate, and the coupon platform makes the pharmacy whole — transparent math, no black box ✅ How the telehealth channel and white label pharmacy models extend the distribution chain beyond retail — and why shipping costs, credit card fees, dispensing fees, and new supply chain partners create gross-to-net and revenue leakage risk for manufacturers not built for it ✅ Why "direct to employer" is a misnomer: PBM contracts prohibit pharma from selling directly to self-insured employers, so third-party transparent administrators have emerged — but plan sponsors need to run the math first, given ERISA complications and PBM contract leverage ✅ How PBMs are now charging fees for hub-like patient support services to manage the exact prior auth complexity they created — a Whack-a-Mole shift of profitability that everyone needs to map before signing anything ✅ Ophelia's three-part practical advice: map the full patient journey and all ecosystem player incentives before building any new model (pharma); treat affordability as a clinical risk factor (clinicians); demand auditable medication abandonment data rather than settling for rebate yield metrics (plan sponsors) WHY THIS MATTERS If collaboration is the next innovation, everyone has to understand the incentives of every player in the ecosystem — not just their own. The same 50% of unfilled GLP-1 prescriptions that looks like runaway pharmacy trend from a plan sponsor's seat looks, from a manufacturer's seat, like half their market going dark — and both sides are making moves that affect each other. Understanding those moves, where fees are being layered on, and when fair profit tips into what Stacey calls profiteering is what this episode maps. TUNE IN NEXT WEEK Next week is the 401-level companion to this one — Stacey goes solo on the PBM and GPO contracting mechanics behind why cash pay became a thing, and why cheaper or better drugs can inexplicably end up off formulary or buried under prior auth. === LINKS ===

Are you dealing with unexpected weight regain or debilitating acid reflux years after your bariatric surgery? You are not alone. In this episode of the Our Sleeved Life Podcast (OSLP), Mel sits down with bariatric surgeon Dr. Betsy Dovec and registered dietitian Hannah Schuyler, the power duo behind Body by Bariatrics. Together, they pull back the curtain on why gastric sleeves commonly lead to new-onset acid reflux, what a "retained fundus" actually means for your hunger hormones (ghrelin), and why weight regain is often a structural issue rather than a personal failure. Dr. Dovec and Hannah share how their patient-first, 100% virtual private practice is completely disrupting hospital-employed healthcare models by slashing 6-month wait times down to just one week. Plus, we explore the powerful, synergistic relationship between bariatric surgery and GLP-1 medications, why insurance hoops are fundamentally broken, and whether or not there's an age limit to reclaiming your vitality. If you've been suffering in silence or beating yourself up over your post-op struggles, this episode is a must-watch masterclass on reclaiming your health, your quality of life, and your anatomy! ✨ Take action on your health today! Go to https://www.bodybybariatrics.com and click "Get Started Now" to verify your insurance or explore virtual consult options.

(June 17, 2026) Records reveal $600MIL estimate for President Trump’s ballroom project, with half from taxpayers. California commission seeks to fix broken public defense system. Dr. Jim Keany, Chief Medical Officer at Dignity Health St. Mary Medical Center in Long Beach, joins The Bill Handel Show for 'Medical News'! Dr. Keany speaks on GLP-1s possibly improving male fertility, the relationship between COVID and cancer, and antibacterial is NOT better than soap.See omnystudio.com/listener for privacy information.

In this episode of The Architect of Resilience, I sit down with Lucas Allen, founder of Boost Your Biology, to discuss what actually drives performance, recovery, hormone health, and longevity. We explore why so many people chase the latest compounds, peptides, and biohacking trends without understanding the biology they're trying to influence. From TRT and GLP-1s to TUDCA, dopamine, sleep, liver health, metabolism, and blood work, this conversation focuses on the foundational systems that determine whether any intervention will actually work. If you're interested in optimizing your health, improving performance, or building a smarter longevity strategy, this episode will help you think differently about the process.  https://chrisduffin.com/ Coaching, Peptides, Supplements, eBooks & Merch, Education, and my Free Community! A deeper dive into coaching, peptides, and regenerative amplification method at https://www.enhancedexecutive.com/

The medical establishment spent decades telling patients that type 2 diabetes is a chronic and irreversible disease. Today's guest decided to prove them wrong.Sami Inkinen is the co-founder and CEO of Virta Health, a company using a combination of nutrition science, remote monitoring technology, and individualized coaching to help patients reverse type 2 diabetes, obesity and other metabolic conditions.  Previously, Sami co-founded Trulia, the online real estate marketplace, serving as COO and president through its IPO and eventual sale to Zillow. He has also held roles at Microsoft and McKinsey, and rowed from California to Hawaii with his wife to raise awareness of the dangers of sugar.Sami joins us to talk about how his own health journey influenced his decision to start Virta, the challenges of scaling in the health space, and the incredible success they've had in treating metabolic disease. Highlights:A personal pre-diabetes diagnosis (2:35)Lessons from Trulia (6:00)Why reversal, not management (9:30)Clinical results and outcomes (12:47)GLP-1s and Virta's approach (15:26)Technology and personalization (17:33)Selling to employers (20:17) Overcoming the status quo (22:33)Building a full-stack team (25:15)Rowing California to Hawaii (28:30)Goals for ‘26 into ‘27 (30:58)Links:Sami Inkinen LinkedInVirta Health LinkedInVirta Health WebsiteICR LinkedInICR TwitterICR Website Feedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, joe@lowerstreet.co

Dr. David Katz, President and CEO of Diet ID, joins Double Take to examine how GLP-1s may affect far more than weight loss—from food noise and addiction to healthcare costs, side effects and shifts in consumer behavior across sectors.

In today's episode, Mandy Connell dives into the world of pharmacy benefit managers, a crucial but often misunderstood aspect of the healthcare system. With the rising costs of prescription drugs, it's essential to understand how these middlemen impact the prices we pay. Joining Mandy is Antonio Ciaccia, president of 3 Axis Advisors, who sheds light on the complex relationships between pharmacy benefit managers, drug companies, and insurance providers. The conversation delves into the history of pharmacy benefit managers, their role in negotiating discounts, and the conflicts of interest that drive up prices. Mandy and Antonio discuss how the system is designed to favor the interests of the middlemen, rather than the patients, and how this leads to inflated prices and unnecessary costs. They also explore the example of GLP-1 medications, which have seen a significant price drop when purchased outside of the traditional insurance system. Plus it's time for our monthly check in with Justin and Brad of Bell and Pollock for Ask the Attorneys! And Dave Fraser from FOX31 stops by for Weather Wednesday!See omnystudio.com/listener for privacy information.

Most men think erectile dysfunction is a bedroom problem and low testosterone is just a fact of getting older. This roundtable makes the case that both are early warning lights for your heart, your metabolism, and your long-term health and that ignoring them can cost you a decade.In this episode, Dr. Gabrielle Lyon sits down with urologists and men's health specialists Dr. Mohit Khera, Dr. Larry Lipshultz, and Dr. Tobias Köhler to discuss:Why a 35-year-old with ED carries a ~15% risk of heart attack or stroke within 7 years, ~3.5x the risk of depression, and ~30% odds of diabetes or prediabetes and why a prescription alone misses all of itWhy "age-related" testosterone decline is largely a misnomer: a healthy man shouldn't drop significantly with age, so falling T usually signals something reversible underneathHow testosterone became the single best blood marker of a man's overall health, and the case for annual screening that almost no man getsWhat the TRAVERSE trial changed when the FDA removed testosterone's cardiovascular warning in 2025, debunking the prostate-cancer and heart-attack fearsThe 2-minute monthly self-exam every man should do to catch testicular cancer early, when it's ~99% curableIf you've been told your symptoms are "just aging" or you love a man who refuses to see a doctor. This conversation shows you how to read the signals your body gives long before a crisis hits.Thank you to our sponsors:Body Health - Use the code LYON20 to get 20% off your first order https://bit.ly/4efgBuMTimeline - Get 20% off your Mitopure order at https://bit.ly/49LSbYzBranch Basics - Save 15% at https://bit.ly/4uuw4x3 with code DRLYONExplore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Find Dr. Larry Lipshultz at:Instagram: https://www.instagram.com/lipshultzmd?igsh=NTc4MTIwNjQ2YQ==Website: https://www.larrylipshultz.com/YouTube: https://www.youtube.com/@DrsAmyandLarryFind Dr. Tobias KohlerInstagram: https://www.instagram.com/tobiaskohlermd?igsh=NTc4MTIwNjQ2YQ==X: https://x.com/sexhealthmd?s=11Find Dr. Mohit KheraInstagram: https://www.instagram.com/drmohitkhera?igsh=NTc4MTIwNjQ2YQ%3D%3DX: https://x.com/DrMohitKheraWebsite: https://drmohitkhera.com/Connect with Dr. Gabrielle Lyon:Instagram: https://www.instagram.com/drgabriellelyon/TikTok: @drgabriellelyonX (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyonChapters00:00 - Introduction01:30 - What doctors got wrong about testosterone05:05 - The prostate cancer myth, debunked07:12 - The best marker of a man's health11:51 - Is age-related decline actually real?14:15 - How obesity crushes testosterone18:11 - Testosterone and reversing diabetes20:06 - GLP-1 versus testosterone25:20 - What "low testosterone" really means29:05 - Dosing, CAG repeats, and microdosing42:34 - The TRAVERSE trial and FDA reversal47:10 - The prostate saturation point56:49 - Peptides, explained01:03:00 - Why ED is a check engine light01:08:26 - The desert of men's health care01:11:06 - The case for annual screening01:16:45 - Varicoceles and male fertility01:20:03 - How to check for testicular cancer01:26:44 - Final advice for menIf you found this episode valuable, share it with someone who would benefit from it.Disclaimers: This episode includes paid sponsorships.The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.

This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

Something strange is happening. People are drinking less alcohol. Not because they joined a recovery program. Not because they found religion. Not because they suddenly became health gurus. Instead, they're taking Ozempic, talking to AI companions, binge-watching Netflix, ordering DoorDash, and staying home. In this solo episode, Shane dives into one of the biggest cultural shifts happening right now. What if alcohol isn't disappearing because society got healthier? What if it's simply being replaced? We explore how GLP-1 drugs like Ozempic are reducing alcohol cravings, why AI companions are becoming a substitute for human connection, and how technology is quietly replacing the role bars and happy hours once played in our lives. This isn't just a conversation about sobriety. It's a conversation about culture, connection, loneliness, comfort, and where we're headed next. The future may be sober. But it might not be for the reasons we think. In this episode: • How Ozempic could disrupt the alcohol industry• Why AI companions are exploding in popularity• The decline of happy hour culture• What technology is replacing in our lives• The hidden connection between alcohol, dopamine, and modern comfort If you've ever wondered where drinking culture is headed, this episode is for you. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Margaux Anbouba, Vogue's Senior Wellness and Beauty Editor is a little bit of a guinea pig when it comes to wellness and beauty trends. “I think I am sometimes too game to try something, but it's a lot of fun,” Margaux admits, “It's a hazard of the job, I suppose.” In this episode, she sat down with Chloe to talk about everything in the space she's been trying lately and to what effect.  They started off by talking about one of the hottest and also most hotly contested wellness options on the market right now: peptides. Margaux recently visited longevity specialist Dr. Amanda Kahn, “the peptide princess” of the Upper East Side, for a lengthy introductory appointment where they covered all of her medical and personal history. “I talked to her about how I'm feeling emotionally, how I'm feeling physically, and then she came back to me with this incredible list of peptides I could try.” Margaux plans to try several different peptides in her stack; among them is an off-label microdose of GLP-1s, in hopes of reducing inflammation throughout her body. She's also trying out GHK, which is meant to help with skin regeneration, and CB-4211 for increased exercise capacity and energy. Relatively new to exercising, Margaux tells Chloe about Emsculpt, a sort of high-intensity electrical muscle stimulation used to tighten and tone. Another similar technology is EMS, which is a low-level stimulation that helps deepen contractions during workouts. “It's sort of Black Mirror-ish in a way,” she says of the device. The first time she tried Emsculpt, after removing the device from her stomach, she was incredibly sweaty. The second time, less so. Generally, practitioners recommend four sessions. The pair also discuss one of Margaux's favorite (and less sweaty) activities—the buccal massage. Buccal refers to the mid-face area right below the cheekbone, and this massage technique takes place both inside and outside the mouth—yes, there will be fingers inside your mouth. Mariam Saprichyan, an esthetician at Karine Kazarian in New York and practitioner of buccal massage, explains that it opens up the lymph nodes, helps with blood flow, and relieves much of the tension we hold in our faces. Not particularly squeamish, Margaux shares another of her latest trials: injecting RADIESSE biostimulating molecules into her scalp. At a swanky room in The Hotel Chelsea, Margaux met with Los Angeles-based Nurse Practitioner Lauren Goodman. “She talked to me about how the scalp is a way to do a lot of lifting without showing anything on the face.” It's informally referred to as a crown lift. And there will always be more to try! To hear their latest Aura ring sleep scores, preferred sunscreens, and Margaux's advice on colonoscopies, check out the episode and subscribe to her weekly newsletter, I Tried That.  Learn about your ad choices: dovetail.prx.org/ad-choices

It's In The News - a look at the top diabetes stories and headlines happening now!   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: fall Detroit and Seattle.   Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.   The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It  does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.   XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. --   Back to the news.. XX   Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.   -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.   XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition

Andy Roddick and Jon Wertheim break down the start of the 2026 grass swing. Andy makes the case for why Wimbledon may be Novak Djokovic's best remaining shot at a major, Ben Shelton's win over Fritz, and Majchrzak beating De Minaur for the title. Plus, Donna Vekić's title run, Emma Raducanu's scheduling debate, Barbora Krejčíková as the ultimate unseeded threat, and a deep dive into Serena's doubles return and whether singles is next. JW also gives an inside look at the new Chris Evert and Martina Navratilova documentary, Chris & Martina: The Final Set, on Netflix June 26th. COMMENT BELOW: Who do you think are the dark horses for 2026 Wimbledon?

Episode 304 reunites The Analysts — Remarkable Retail's celebrated panel of Forrester's Sucharita Kodali, Guggenheim's Simeon Siegel, and GlobalData's Neil Saunders — to take stock of retail coming out of earnings season. Steve Dennis and Michael LeBlanc open on the paradox of 2026: results are largely strong, sentiment is dismal. Simeon argues the link between the two is "tenuous at best" — people talk one way and spend another. Neil has the data: roughly 60% of shoppers who expect the economy to worsen still spent more than a year ago, propped up by spring tax refunds that won't repeat. Then the K-shaped economy. Higher-income households drive most of the real volume growth; middle-income shoppers prop up value growth mainly because prices are higher. Sucharita revisits "peak ambiguity" and the "vibe session," noting record sales barely outrun stubborn inflation. The panel unpacks the standouts — Ross's 17% comp, Victoria's Secret up 15% — and debates GLP-1's role in surging apparel and beauty: wardrobe replacement, new confidence, trading up to statement pieces. On turnarounds, Simeon lands the episode's sharpest thesis: brands "ubiquitize" and peak around $3–4 billion in the US. Lululemon got too big, over-distributed, and over-earning — so the bad sales have to "walk out the door" before the brand can re-elevate, the same lens that frames Nike's long reset. He and Sucharita draw the Gap parallel ahead of Simeon's on-stage interview with Mickey Drexler, noting Old Navy now dwarfs Gap itself. Neil makes the case for Macy's under Tony Spring — basics fixed first, satisfaction and visitation improving — while Steve stays skeptical of the pace. Next, the DTC reckoning. Simeon reframes his old "DTC is not all it's cracked up to be" call as "anti-anti-wholesale": outside high-margin luxury, nearly every brand needs a healthy wholesale business — and stores remain the best channel because "the customer is your employee." Sucharita pushes back on the AI narrative, reminding everyone it's far more than generative hype, as the panel digs into why scaled players — Amazon, Walmart, Costco, off-price — keep compounding through retail media, marketplaces, and flywheel economics. It closes on the wealth effect, trillion-dollar market caps, and whether a market correction could rattle high-end spending — then rapid-fire hot takes: brands to watch (Cozey, Ross Stores, Goyard) and what's on each analyst's radar, from inflation and surging oil prices to a quiet "middle of the doughnut" news lull and an election year's hunt for stability. Join us at the CommerceNext Growth Show in New York June 23rd and 24th with this exclusive discount code for 10% off general admission tickets and FREE retail tickets: Your code is "REMARKABLE" . See you in the Big Apple! About UsSteve Dennis is a strategic advisor and keynote speaker focused on growth and innovation, who has also been named one of the world's top retail influencers. He is the bestselling author of two books: Leaders Leap: Transforming Your Company at the Speed of Disruption and Remarkable Retail: How To Win & Keep Customers in the Age of Disruption. Steve regularly shares his insights in his role as a Forbes senior retail contributor and on social media.Michael LeBlanc is a senior retail advisor, keynote speaker and media entrepreneur. Michael has delivered keynotes, hosted fire-side discussions hosted senior retail executive on-stage in 1:1 interviews worldwide. Michael produces and hosts a network of leading retail trade podcasts, including The Remarkable Retail Podcast, The Voice of Retail The Food Professor, The FEED powered by Loblaw and the Global eCommerce Leaders podcast. He has been recognized by the NRF as a global Top Retail Voice for 2025 and 2025 and continues to be a ReThink Retail Top Retail Expert for the fifth year in a row.

Charles Duhigg is a Pulitzer Prize-winning journalist and staff writer at The New Yorker. He is the author of The Power of Habit, Smarter Faster Better, and Supercommunicators. His work focuses on the science of habits, productivity, decision-making, and human connection.In this episode of Summation, Charles and Auren discuss:why producing the words is only 10% of an author's job, and the 90% AI can't dowhat GLP-1s actually do to the brain the serendipity tax: why you pay for five dead-end dinners to get the one that changes your lifethe three skills that separate supercommunicators from everyone elseYou can find Auren Hoffman on X at @auren and Charles Duhigg on X at @cduhigg

You're trying to recover. The whole world seems to be on a shot, shrinking on purpose, celebrating it loudly. And somewhere underneath all of that, a quieter question keeps surfacing in you: is what I'm doing to my body actually hurting me? That question is the whole episode. If you've been afraid to ask it out loud — this one's for you. In this one, Lindsey opens up about the moment "just trying to be healthy" stopped serving her life and started running it, what restriction quietly takes that no scale can show, and the truth she wants you to hold onto in a culture that keeps telling you to make yourself smaller. This isn't a meal plan. It's not a fear list. It's an honest word, woman to woman, for the one who's wondering if she's okay. What this episode is really about How "wellness" can quietly become the cage The cultural moment we're in — GLP-1s, shrinking-culture, and what it's like to try to recover in the middle of it The real, honest answer to "is this hurting me?" — without giving the disorder one more thing to monitor What restriction takes that no one talks about: not what you see in the mirror, but what makes you you Why your wondering is the wisest part of you The truth that you were chosen to be free — right now, as you are A few lines from the episode "A lot of us didn't fall into this through vanity. We fell in through wellness." "You're not losing what you see in the mirror. You're losing what makes you you." "If that question is in you at all — listen to it. That's not fear talking. That's the wisest part of you, the part that's still on your side." "Health was never the number. It never was." "You can feel the storm and not be the storm." "You were chosen to be free. Not free once you fix it. Free right now, as you are, in the middle of the struggle." If something in this episode is sitting with you You don't have to untangle this alone — and you were never supposed to. Lindsey works one-on-one with women who are ready to stop white-knuckling recovery by themselves, and her Freedom Formula experience is the space where you'll be supported and surrounded as you do the real work of coming home to yourself. Both live at www.herbestself.co.  And if you're in a harder place than a program can hold right now — that's not failure, and you're still worthy of support today. Please reach for it. Talk to your doctor, a therapist, or the National Alliance for Eating Disorders helpline. You're worth asking for help to reach freedom. Your next steps:

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down witH ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?In this episode:✅ Survodutide obesity and liver fat reduction data✅ Mazdutide Phase 3 obesity and diabetes results✅ UBT251 triple agonist weight loss data✅ Berobenatide (MET-097) long-acting GLP-1 updates✅ CagriSema diabetes and obesity trial results✅ Zenagamtide (Amycretin) injectable and oral development✅ Petrelintide amylin agonist info✅ Future GLP-1, GIP, glucagon, and amylin therapiesThe future of obesity medicine is no longer just about who produces the most weight loss. It's about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.Read more obesity medicine news at obesity.news

Rebecca Morrison is healthy by many measures. But like millions of people today, she finds herself wondering whether or not she should be taking a GLP-1 drug. What's the right thing to do? This episode explores how this new class of weight loss drugs is reshaping our healthcare choices, and the landscape in which we make them.You can read more about Rebecca Morrison's story in her novel, The Blue Dress, released March 2026. This episode features:Rebecca K. Morrison: Writer.Mara Gordon, MD: Primary Care Physician at Cooper University Hospital and Assistant Professor of Family Medicine at Cooper Medical School of Rowan University.Alexandra Brewis, PhD: Regents Professor and President's Professor at the School of Human Evolution and Social Change at Arizona State University.Jeffrey Kahn, PhD, MPH: Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics.“playing god?” is a podcast by the iDeas Lab at the Johns Hopkins Berman Institute of Bioethics. To read a transcript of this episode, visit the iDeas Lab website at https://bioethics.jhu.edu/pgs2e5.The Johns Hopkins University Sesquicentennial is proud to support this podcast. JHU celebrates 150 years of pioneering education and research—advancing knowledge to meet the challenges of every generation. Learn more at 150.jhu.edu.

Today on the Woody and Wilcox Show: Chelsea's late and finding ticks; Boy George uses AI to re-record Karma Chameleon; GLP-1 medications improve male testosterone levels and sperm count; World Cup is introducing new countries to people; Women are gatekeeping Midol; Pigeons can spot cancer; New hockey show on Netflix; And more!

Craig Emmerich spent a decade eating low-carb and feeling great — until he wasn't. What followed was a quarter-million dollars, a chronic Lyme diagnosis, and a hard-won education in what diet alone simply cannot do.In this conversation, Craig and Dr. Ovadia pull apart one of the most seductive myths in the metabolic health space: that the right food is always the right answer. They talk protein thresholds, personal fat limits, the case for bio-identical hormones, and the nuanced reality of GLP-1s — all filtered through 20-plus years of clinical observation and thousands of client testimonies.What emerges is a framework built not on ideology but on context. The question isn't which diet is correct. The question is what your body actually needs right now — and whether you're asking that question honestly.Craig and Maria Emmerich's new book, The Art of Metabolic Health, is available at ketomaria.com.BIG IDEAThe number one failure of any diet is noncompliance — and the number one failure of any health strategy is mistaking the tool for the answer.Craig Emmerich Contact InfoWebsiteKetoMaria.comhttps://ketomaria.com/Newest BookThe Art of Metabolic Health https://keto-adapted.com/product/the-art-of-metabolic-health/Send Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Order at Amazon: Stay Off My Kitchen Table  Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Ready to take control of your health?  Grab Dr. Ovadia's brand new book Stay Off My Kitchen Table now! This isn't just another diet book; it reveals why it's not just what you eat, but what your body actually absorbs that determines your health.If you're struggling with low energy, stubborn weight, or feeling like “healthy eating” isn't working… this book shows you exactly how to fix it.Learn how to reset your gutEliminate hidden foods sabotaging your progressUnlock real energy, metabolism, and longevityDon't wait until it's too late. Take action today. Get your copy of Stay Off My Kitchen Table now.Learn More:Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart HealthTheme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey (c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

Sports medicine physician,endurance athlete and 1% Better Podcast host  - Dave Lipman - checks in for a wide-ranging conversation covering the realities of podcasting, the future of endurance technology, recovery methods, supplements, sleep tracking, heat adaptation, longevity trends, GLP-1s, peptides, and where the line should be drawn between performance enhancement and fair competition. Dave Lipman Links: Instagram: https://www.instagram.com/drdavidlipman/ 1% Better Podcast Instagram: https://www.instagram.com/onepercentbetterpod/| 1% Better Podcast on Spotify: https://open.spotify.com/show/4bG2U3dciEduX8c3PUtkrQ Matt Fox Links: Instagram: https://www.instagram.com/mattinglisfox/ Coaching: https://www.sweatelitecoaching.com/ Supporters Club: https://www.sweatelite.co/supporters YouTube: https://www.youtube.com/@SweatElite Matt welcomes Dave back to the podcast and the pair begin by discussing the realities of producing endurance content. They talk about the challenges of scheduling guests, dealing with cancellations and technical issues, recording in person versus remotely, and why some of the best conversations happen when the host and guest don't know each other particularly well beforehand. Dave also shares his podcast inspirations, what he currently listens to, and the endurance personalities he would most like to interview. The conversation then shifts toward the future of endurance performance technology. Dave discusses continuous lactate monitoring, multi-analyte sensors capable of tracking biomarkers such as glucose, ketones, cortisol, and hormones, as well as emerging ventilation and respiratory wearables. They explore whether future devices will be able to separate metabolic stress from mechanical and neuromuscular load, creating more useful insights than current metrics alone. Matt and Dave discuss the balance between useful data and over-analysis, touching on sleep tracking, orthosomnia, and how athletes can become overly reliant on wearable feedback. Dave explains why subjective feel still matters and why training should ultimately enhance enjoyment rather than create more stress. The discussion moves into supplements, with Dave outlining his practical framework for evaluating evidence and deciding what is worth using. They cover bicarbonate products such as Maurten Bicarb and Nomio, creatine, beta-alanine, beet nitrates, taurine, and the supplement trends currently gaining traction in endurance sport. Recovery strategies are another major focus. Dave reviews the evidence surrounding ice baths, sauna use, heat adaptation, active versus passive heat exposure, and how timing these interventions incorrectly may blunt training adaptations. They also discuss sweat rate adaptations, the interaction between heat and altitude training, and examples of accidental training breakthroughs that emerged from environmental stress. The final section of the conversation examines the rapidly growing longevity and biohacking space. Matt and Dave discuss Bryan Johnson, GLP-1 medications, peptides, anti-aging interventions, anti-doping gray areas, and whether amateur athletes should be held to different standards than professionals. The discussion expands into super shoes, emerging performance technologies, and how the sport may need to adapt as new forms of enhancement become increasingly accessible. Episode Chapters 00:00 Welcome Back Dave 01:01 Podcasting Struggles 02:59 Remote vs In Person 05:06 Editing Norwegian Method 06:56 Podcast Inspirations 07:58 What We Listen To 12:26 Dream Guests List 13:51 Better Interview Flow 16:43 Future Endurance Tech 19:53 Continuous Biomarkers 21:55 Mechanical Load Insights 27:06 Cortisol and Lactate Nuances 31:24 Lactate Compartments 32:56 Tech and Overthinking 36:06 Train for Enjoyment 36:44 Sleep Tracking Pitfalls 40:13 Supplements Framework 47:21 Creatine, Beta-Alanine, and Beets 53:44 Taurine and Trends 56:31 Ice Baths Net Effect 01:02:37 Sauna Heat Adaptation 01:05:52 Heat Training Benefits 01:06:28 Sweat Rate Tradeoffs 01:07:30 Active vs Passive Heat 01:08:38 Heat Plus Altitude Synergy 01:09:15 Accidental Breakthrough Block 01:12:05 Longevity and Bryan Johnson 01:13:15 Complex Systems and Lifestyle 01:17:28 GLP-1s and Doping Rules 01:22:39 Peptides Gray Market Risks 01:23:44 Amateur Standards and Fairness 01:26:28 Super Shoes and Gray Areas 01:33:22 Wrapping Up and Podcast Plug

Wir sprechen heute über die top defensive Dividendenaktien der letzten Jahrzehnte. Dabei geht es um Unternehmen wie McDonald's, Coca-Cola, Pepsi, Hershey, Constellation Brands und viele weitere große Namen, mit denen Anleger in den vergangenen Jahrzehnten in der Regel gut gefahren sind. Diese Unternehmen haben sich insbesondere dadurch ausgezeichnet, dass sie selbst in Krisenzeiten zuverlässig Dividenden gezahlt und diese in den meisten Fällen sogar kontinuierlich erhöht haben. Doch nun zeichnet sich ein immer stärker werdender Trend rund um GLP-1-Medikamente ab. Die entscheidende Frage lautet daher: Könnten diese Medikamente dazu führen, dass die Erfolgsära dieser Dividendenstars ihrem Ende entgegengeht?
 ► Hole dir jetzt deinen Zugang zur brandneuen BuyTheDip App! Jetzt anmelden & downloaden: http://buy-the-dip.de
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Meinen BuyTheDip-Podcast mit Sebastian Hell und Timo Baudzus findet ihr hier: https://buythedip.podigee.io
 ► Schau Dir hier die neue Aktion der Rendite-Spezialisten an: https://www.rendite-spezialisten.de/aktion
 ► TIPP: Sichere Dir wöchentlich meine Tipps zu Gold, Aktien, ETFs & Co. – 100% gratis: https://erichsen-report.de/
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Zum Zeitpunkt der Erstellung dieses Beitrags war der Autor, Lars Erichsen, in folgenden der besprochenen Finanzinstrumente selbst investiert: Diageo, Unilever. Geplante Änderungen: Keine. Weitere Informationen entnehmen Sie bitte unserem Transparenzhinweis zum Umgang mit Interessenskonflikten: https://www.lars-erichsen.de/transparenz-und-rechtshinweis

If you've been anywhere near the internet in the last couple of years, you've heard about Ozempic and GLP-1 drugs. You've seen the before-and-afters. Maybe a friend asked if you should try it too. And if you're like most of the women Dr. Shivani works with, you may feel confused. The results look real, but something feels off. Are we treating a symptom? Are we missing something deeper?In this episode, Dr. Shivani Gupta tells the story of Veronica, a client who came to her terrified after a bad experience with GLP-1 medication, but still wanting to lose weight, reduce inflammation, and feel like herself again.Through Veronica's story, Dr. Shivani breaks down what GLP-1 actually is, why so many people have a weakened natural GLP-1 response, and how Ayurveda has been supporting this same pathway through agni, bitter foods, gut health, and daily rhythm.You'll learn:What GLP-1 actually is and why your body already makes itWhy GLP-1 drugs work on inflammation, not just appetiteWhy processed food, stress, sleep, and gut imbalance can blunt your natural GLP-1 responseThe Ayurvedic concept of agni and how it connects to GLP-1 biologyNatural ways to support your body's GLP-1 pathway using food, herbs, and rhythmWhat GLP-1 drugs may be helpful for, and what Dr. Shivani wants women to understand firstHow Veronica rebuilt her foundation naturally

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Professor Carel le Roux from University College, Dublin and Ulster University. They discuss the trial evidence that has emerged over the last 20 years for both bariatric surgery and the newer GLP-1 medications, focusing particularly on reductions in cardiovascular outcomes. They also discuss where the field of obesity intervention might head over the next five years and how metabolic surgery will continue to have an important role. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/early/2026/02/23/heartjnl-2025-326812

Links, cheatsheet, private group and more: https://hunterwilliamshealth.com/linksKPV is the most underrated peptide out there. Almost nobody talks about it. In my opinion it should be one of the most demanded peptides we have. If I had to choose, I'd take it over BPC and TB-500 every single time.Here's why. KPV is a tiny three amino acid fragment of alpha-MSH. It directly blocks NF-kappa B, the master switch your body uses to turn inflammation on. Most peptides work around the edges. KPV shuts the alarm off at the door.In this one I cover all of it. What KPV is and how it works. Who actually benefits. Dosing by tier and by purpose. How to stack it with BPC, TB-500, LL-37, and your GLP-1. What to track on bloodwork. Cycling, sequencing, troubleshooting, and a full FAQ.If you've ever run a protocol that worked and then stalled out, this one is for you. Inflammation is almost always the rate-limiting step in healing.Make sure you're on the email list. And come join us in the Axion Collective for live coaching every Thursday.⚠️ For research and entertainment purposes only. ⚠️

What happens when you combine the clinical expertise of a registered dietitian with the comprehensive training of a board-certified family medicine physician? You get a powerful, preventative approach to healthcare that looks at the whole person.In this episode of Real Fuel with SLS, Stevie Lyn Smith catches up with longtime college friend and colleague, Dr. Alex Ford, DO, RD. Dr. Ford shares his unique journey from studying dietetics at Buffalo State to navigating the rigorous world of medical school, serving as Chief Resident at the prestigious Cleveland Clinic, and earning a spot on Albany's 40 Under 40 list. They dive deep into the gaps in traditional medical education regarding nutrition, the rise of GLP-1 medications, and how to champion true, preventive lifestyle medicine.In this episode they chat more about:The anatomy of whole-person careGLP-1s as tools as part of lifestyle medicineThe foundational pillars for every human looking to improve healthDr. Ford's career path and educationMaking nutrition information digestible and easy for individuals to apply to their livesThe reality of nutrition education in medical school (or lack thereof)And so much more!Stay Connected:Stay up to date with Dr. Ford: https://www.dralexford.com/Connect with Dr. Ford at  info@neotritionbrands.com, for general questionsFollow Stevie on Instagram: @stevielynlynJoin Stevie's newsletter: Stevie Lyn Nutrition newsletterLearn more about Dr. Alex Ford: If you enjoyed this episode, please leave a 5-star rating and review on Apple Podcasts or Spotify—it helps more athletes and health-conscious individuals find the show!

Professor Tim Spector, co-founder of ZOE, joins Performance People to explain how gut health can influence mood, energy, cravings, focus and long-term health.In this conversation, Tim explores the gut-brain connection, why brain fog may be linked to what we eat, the problem with ultra-processed foods, the benefits of fermented foods and plant diversity, and why he believes GLP-1 drugs could be one of the most important medical discoveries of his career.He also explains why calorie counting and willpower alone have failed so many people, and why the future of nutrition may be far more personalised, preventative and performance-focused.Tim's book, Ferment, now available in paperback at Amazon or wherever you get you books.___FAQsWho is Professor Tim Spector?Professor Tim Spector is a scientist, author, doctor and co-founder of ZOE, known for his work on nutrition, gut health, the microbiome and personalised health.What does Tim Spector say about the gut-brain connection?Tim explains that the gut and brain are closely connected, with the gut sending signals that may affect mood, energy, appetite, focus and mental performance.Can food affect brain fog and concentration?Yes. Tim discusses how sugar spikes, energy dips and inflammation may contribute to brain fog, fatigue and poor concentration.What does Tim Spector recommend for gut health?He talks about eating 30 plants a week, adding more colour and variety to your diet, increasing fibre, using herbs and spices, and regularly including fermented foods.What are fermented foods?Fermented foods include things like kefir, yoghurt, kimchi, sauerkraut and other foods that may help support gut health and reduce inflammation.What does Tim Spector say about GLP-1 drugs?Tim describes GLP-1 drugs as one of the most important medical discoveries of his professional career, but argues they should be combined with nutrition education and long-term behaviour change.Why does Tim Spector criticise calorie counting?He argues that calorie counting and restriction have failed many people because they do not address appetite signals, food quality, gut health or the wider food environment.How is this episode relevant to performance?The episode explores how what we eat can affect focus, energy, mood, decision-making and long-term health, all of which are central to everyday performance.___00:00 Why GLP-1 Drugs Could Transform Public Health01:34 Professor Tim Spector on Food, Mood and Performance02:32 Can Your Gut Change the Way You Think?06:58 Can Changing Your Microbiome Change Your Personality?08:05 The Food Experiment That Gave Tim Spector Brain Fog12:21 How Blood Sugar Spikes Affect Focus and Energy19:17 Why What You Eat Is Crucial to Mental Performance21:37 How to Improve Your Diet and Gut Health24:35 The Benefits of 30 Plants and Fermented Foods34:48 The Truth About GLP-1s, Weight Loss and Willpower___The Performance People podcast, in partnership with J.P. Morgan Private Bank, talks to high-performers in the world of sport and beyond, to bring defining moments, hard-earned insights and expert advice to everyday performance. New episodes every Tuesday.___ainslie + ainslie NIGHT POWDER, winner of Best Sleep Supplement in the GQ Sleep Awards 2025.We love performance, which is why we've launched ainslie + ainslie – the first supplement brand to be developed inside elite sport. Now available for everyone. Find out more at www.ainslieainslie.com___The views and opinions expressed on Performance People are those of the guests and hosts, and do not necessarily represent the views of ainslie + ainslie, J.P. Morgan Private Bank, or any affiliated organisations.This podcast is produced by Gameface Limited and is intended for general information and entertainment purposes only.© Gameface Limited 2026. All rights reserved.Connect with Performance PeopleHit subscribe today for the latest.

(SPOILER) Today's Daily Roundup covers the great weekend in Vegas for the 10th Annual Fan Appreciation Party, attending the No Doubt concert Friday night, Sunday's fun gambling story, and Vanity Fair's expose on the Unwell Network finally gets released.Music written by Jimmer Podrasky (B'Jingo Songs/Machia Music/Bug Music BMI)Ads:Ollie - Get 70% off when you subscribe to your Welcome Kit. Go to https://ollie.com/RealitySteve use Promo Code: RealitySteve for 70% off. Zenni - Online eyewear shop. Now is the time for that long overdue purchase of eyeglasses or sunglasses. Go to https://zenni.com/podcast Promo Code: Podcast15 for 15% off your first order. Ro - https://ro.co/RealitySteve to see if you're eligible for the new GLP-1 pill on Ro. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Andrew Paul Koutnik joins Mark Bell and Nsima Inyang to break down type 1 diabetes, type 2 diabetes, insulin resistance, glucose control, low-carb diets, GLP-1 drugs, obesity, and why the modern food environment is making metabolic health harder than ever.Andrew was diagnosed with type 1 diabetes as a teenager after a terrifying health scare that landed him in the ICU. Since then, he's spent his life studying metabolism, nutrition, insulin, and performance — not just in the lab, but through his own daily experience managing the disease.This episode covers the difference between type 1 and type 2 diabetes, why glucose control matters so much, how carbs impact blood sugar, the role of insulin, why many people are metabolically unhealthy, and what people can do to better manage their health.Special perks for our listeners below!

People using GLP-1 drugs like Ozempic lose about 7% of their facial fat for every 22 pounds of body weight lost, resulting in a hollow, prematurely aged look Rapid weight loss may drain key nutrients and fatty acids that your body needs to produce collagen and maintain firm, healthy skin "Ozempic face" may indicate an energy imbalance — your cells lose the fuel and structural support they need to keep skin elastic and vibrant Avoiding GLP-1 drugs, eliminating seed oils, and restoring gut health may support metabolic recovery, which research suggests could help restore facial tone and fullness over time Natural tools like polyphenol-rich foods and the right carbohydrates may support weight management without draining your body's nutrient reserves

Weight loss changes more than your body. It can change how you see yourself, how others treat you, and the story you tell yourself every day. In today's episode, I'm joined once again by registered dietitian, life coach, and Wellness Cottage co-founder Kim Lovely to talk about the emotional side of weight loss that so many women experience but rarely discuss. From body dysmorphia and identity shifts to navigating comments from others and adjusting to life after GLP-1s, Kim shares powerful insights on how to care for your mind as your body changes. For more on Kim, follow her on:Website: https://kimlovelyrd.com/ Instagram: https://www.instagram.com/kimlovely_nutritionist/ Facebook: https://www.facebook.com/lovesnutrition/ Faded to Fabolous Podcast: https://www.fadedtofabulous.biz/podcast-1 Thanks to my Sponsors:Leesa: Go to Leesa.com for 25% off PLUS get an extra $50 off with promo code OVER50 Manukora: Head to Manukora.com/FLOURISHING to save 31% plus $25 worth of free giftsQualia Life Sciences: Magnesium, multiplied. 10 forms for total support. Go to qualialife.com/FLOURISHING to get 50% off and save an extra 15% with the code FLOURISHING Mud/Wtr: Go to mudwtr.com/OVER50 and use code OVER50 for 43% off. Puori: Go to Puori.com/FLOURISHING and use the code FLOURISHING at checkout for this limited offer. Bubs Naturals: Live Better Longer with BUBS Naturals. For a limited time get 20% off your entire order with code FLOURISHING at bubsnaturals.com Keep in Touch:Website: ⁠⁠⁠⁠⁠⁠⁠https://dominiquesachse.tv/⁠⁠⁠⁠⁠⁠⁠Book: ⁠⁠⁠⁠⁠⁠⁠https://dominiquesachse.tv/book/Insta: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/dominiquesachse/Facebook: ⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/DominiqueSachse/TikTok: ⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@dominiquesachse?lang=enYouTube: ⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@dominiquesachsetvHave a question for Dominique? Submit it here for a chance to have it answered on the show! https://forms.gle/MpTeWN1oKN8t18pm6 Interested in being featured as a guest? Please email ⁠⁠⁠⁠⁠⁠⁠courtney@dominiquesachse.tv⁠⁠⁠⁠⁠⁠⁠ We want to make the podcast even better. Help us learn how we can: ⁠⁠⁠⁠⁠⁠⁠https://bit.ly/2EcYbu4⁠⁠⁠⁠⁠⁠⁠Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, I sit down with Houston-based plastic surgeon Dr. Vinaya Rednam, who specializes in surgery for patients who've lost massive amounts of weight. We get into everything from GLP-1 medications and how they affect tissue quality, to the most common body contouring surgeries after major weight loss, and what you need to know before going under the knife.  Topics Discussed: → Who is a good candidate for massive weight loss body contouring? → How do GLP-1 medications affect loose skin and surgical results? → Can you prevent loose skin while losing weight? → What should you know before getting a lower body lift? → Are non-surgical skin tightening treatments worth it? → What should you expect from arm lifts, breast lifts, and thigh lifts? → When is the right time to consider surgery after major weight loss?

I'm exposing the truth about how high-protein foods can mimic the appetite-suppressing effects of weight loss drugs but with benefits instead of side effects. When you use Ozempic or similar medications, up to 40% of your weight loss can come from muscle, devastating your metabolism and setting you up for rebound fat gain. Protein, however, works naturally with your body's hunger hormones—slashing ghrelin for 3+ hours, maintaining healthy leptin levels, and boosting PYY—all while providing essential amino acids for mood-regulating neurotransmitters. I'm sharing my complete Ozempic-mimicking protein protocol, including the magic combination with fiber that naturally stimulates GLP-1 production (the same hormone triggered by those expensive medications). Plus, protein's thermogenic effect means you'll burn more calories digesting it, and when paired with resistance training, you'll maintain or even build metabolism-boosting muscle rather than losing it. What you'll learn: How protein naturally controls hunger through three key hormonal pathways Why Ozempic and similar drugs can cause dangerous muscle loss (up to 40%) The specific protein amounts needed at morning and evening "bumper meals" to control cravings Which protein sources provide the best metabolic benefits How to pair protein with fiber for maximum GLP-1 production The importance of resistance training in a protein-focused weight loss approach Why protein shakes outperformed Ozempic in a recent study for fat loss while preserving muscle Love the podcast? Here's what to do: Subscribe to the podcast. Leave a review. Text a screenshot to me at 813-565-2627 and wait for a personal reply because your voice is so important to me. Learn more about your ad choices. Visit megaphone.fm/adchoices

If you've been eating less, exercising more, and still experiencing unwanted body changes, this episode is for you. Natalie Jill, a Licensed Master Sports Nutritionist and functional fitness trainer, joins Dr. Stephanie for a peer-to-peer conversation between two women in the fitness industry who have seen the same broken patterns and concluded that the plan most women follow is not suitable for them. Natalie's journey from rock bottom to 13 magazine covers in her 40s and 50s was not due to a better diet plan, but rather a complete overhaul of her False Assumed Truths (F.A.T.). She discusses the mechanics behind why chronic cardio is counterproductive in midlife, the accelerating bone loss caused by ellipticals, the falsehood of three sets of twelve, and the necessity of changing beliefs before any protocol can work. This rare episode features two practitioners in the same space, with the same audience, comparing notes honestly. Episode Overview: (0:00) Intro/Teaser (1:08) Cardio vs. Lifting, Body Weight Training & the Supplement Swap (7:52) The Best Thing That Happened to My Body After 40 (14:44) From Rock Bottom to 13 Magazine Covers (28:45) The Fitness Industry Did Midlife Women Dirty (34:00) Why Everything Works in Your 20s (36:20) The Problem with Cardio Machines, Calorie Counts & the Elliptical (43:10) Low Impact Is Killing Your Bones (49:15) False Assumed Truths: The Belief System Running in the Background of Every Midlife Woman ((56:20) Is Menopause Weight Gain Inevitable? (1:01:00) GLP-1s, Muscle Loss & Why There Is No Easy Button (1:06:20) This Is Why I Lift (1:09:26) What a Real Training Week Actually Looks Like (1:12:37) After Party: Stephanie's Highlights Resources mentioned in this episode: https://drstephanieestima.com/podcasts/ep473 We couldn't do it without our sponsors: YOUNG GOOSE - Skin aging isn't defined by wrinkles. It's defined by skin quality. Head over to https://drstephanieestima.com/younggoose and use code BETTER for 10% off your first purchase. BON CHARGE - Achieve glowing skin, gain more energy, and uplevel your recovery practice with a suite of red light products. Get 15% off at https://boncharge.com/better with code BETTER. PIQUE - Designed to deeply hydrate, enhance skin elasticity & firmness and support sustained energy—exactly what we need during this stage of life. Start your daily ritual today and elevate your routine. Head to https://piquelife.com/drestima. INCREDIWEAR - Whether you're an athlete, dealing with chronic joint pain, or just someone who wants to feel better in your body — this is worth trying. Head to https://drstephanieestima.com/incrediwear and use code DRSTEPH20 for 20% off your order. RAPID REBOOT - Weekend warrior, a competitive athlete, or a parent of one — this is a game-changer for the whole household. Go to https://drstephanieestima.com/rapidreboot and use code DRSTEPHANIE for 10% off. ****************************P.S. When you're ready, here are two ways Dr. Stephanie can help you:Subscribe: The Mini Pause — My weekly newsletter packed with the most actionable, evidence-based tools for women 40+ to thrive in midlife.Build Muscle: LIFT — My progressive strength training program designed for women in midlife. Form-focused, joint-friendly, and built for real results. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode, Jason is in Ireland finding himself so Mary and Keith welcome the crew from Woodworking is Bullsh*t, Paul Jasper and Erik Curtis, to talk about the rise and fall of social media, procrastination, motivation, how to raw dog your downtime and GLP-1?? But somewhere in all the palaver, we make some good points...we think...Check out Paul and Erik's AMAZING Podcast:https://podcasts.apple.com/be/podcast/woodworking-is-bullshit/id1724046445Be sure to check out Bits & Bits at www.bitsbits.com and use coupon code MORSELS15 to save 15% on your order of router and/or CNC bits. Be sure to hit up Katz-Moses Tools at www.KMTools.com - cool tools at a fair price. If it's on their website, it's in Jonathan's apron. www.kmtools.com **And check out the new Katz Moses toolless adjustable countersink and new sharpening jig and sliding stop block. Oh, and don't forget about his new aluminum channel French Cleat system with some bad azz 3D printed accessories that lock in place!! WTB Woodworking's latest giveaway is a ~$1,000 JET Power Tools DC-1100VX-CK Dust Collector with Vortex Cone! Suck me sideways! Register at wtbwoodworking.com/giveaway. Registration is good through midnight EST on Thursday, July 24th. And be sure to check out WTB Woodworking in person at 390 Pike Road, Unit 2, Huntingdon Valley, PA for lumber, slabs, woodworking tools and MORE!! Or shop online and earn yourself some Burkell bucks for every dollar you spend! Go to wtbwoodworking.com to shop online.Help us support Grit-Grip!! A revolutionary new breed of double-sided sanding sponges that we all LOVE! Check it out at https://grit-grip.com/ and use code "shopsounds" at checkout to get a free sanding block!GorillaWood Glue is the #1 most-used wood glue brand among woodworking pros! Go to gorillatough.com/shopsounds to learn more about their amazing line up of products! Gorilla. Trusted by pros, easy for everyone.The Bourbon Blade: https://www.bourbonmoth.com/shop/p/the-bourbon-blade-original-pocket-chiselIf you'd like to support us on Patreon and have access to our irreverent aftershow, you can sign up here: https://www.patreon.com/shopsoundspodcastYou can find us on Instagram, Youtube, Facebook and TikTok (maybe): Bourbon Moth Woodworking and Keith Johnson Woodworking and Kodamari Design

This week, leading into Father’s Day weekend, we are celebrating fathers all around.  We touch on the topic of hair, the best fries across the state, and how GLP-1’s could be threatening McDonald’s bottom line.

Are you trying to figure out your next steps after losing weight on GLP-1 medications? In this episode of Big Butts No Lies, Mavi sits down with board-certified Portland plastic surgeon Dr. Aric Aghayan to talk about the reality of body contouring after significant weight loss. Dr. Aghayan breaks down why a traditional tummy tuck only addresses two-dimensional, post-pregnancy changes in the front, and why anyone who has lost more than 50 pounds is likely a much better candidate for a 360-degree 3D body lift. We dive deep into the absolute complexities of the belly button, including how surgeons use "origami" techniques to create a completely new belly button when the original tissue has been severely stretched out. Dr. Aghayan also introduces us to Preservation Breast Augmentation—the biggest innovation in breast surgery since the 90s—which uses a balloon technique to protect your natural nerves and blood vessels, eliminates lifting restrictions, and allows patients to get back to the gym in just one week. Plus, we get his unfiltered, rapid-fire takes on the "religion" of lymphatic massages, his rules on post-BBL sitting, and when he chooses to use surgical drains versus going drain-free.⏱️ Chapters00:00 — Welcome to Big Butts No Lies00:40 — Introduction to Dr. Aric Aghayan 01:15 — Tummy Tuck vs. 3D Body Lift 03:39 — Introducing The Recovery Diaries 04:32 — Fixing the Belly Button After Weight Loss 08:34 — What is Preservation Breast Augmentation? 13:47 — Restoring Buttock Volume After Weight Loss 18:06 — Why I Became a Plastic Surgeon 21:16 — Team Drains vs. No Drains 22:53 — Are Lymphatic Massages Necessary? 27:25 — When Can I Sit After A BBL?30:04 — What Are You Rules On Compression? Available on YouTube, Spotify, and Apple Podcasts. Hit subscribe so you never miss a truth bomb!

What do you want your new normal to be?If you're currently taking a GLP-1 medication, you've probably heard people talk about reduced appetite, fewer thoughts about food, lower energy levels, nausea, and significant weight loss. For many people who have struggled with weight management for years, those changes can feel like a welcome relief.In this episode of Life During and After GLP-1, I explore an important question that often gets overlooked: what do you ultimately want your day-to-day life to look like?We discuss the trade-offs that can come with GLP-1 medications, the importance of thinking beyond short-term weight loss, and why it's worth considering how your energy, strength, activity levels, and overall quality of life fit into the bigger picture.This isn't about telling you whether GLP-1 medications are right or wrong. Those conversations belong between you and your healthcare provider. Instead, this episode is about helping you think critically about the lifestyle you're building and whether it aligns with the life you want to live long-term.Topics Covered:• Defining your new normal• Life during and after GLP-1 medications• Appetite changes and food noise• Energy levels and daily activity• Strength, muscle mass, and performance• Long-term lifestyle considerations• Weight loss versus quality of life• Marketing messages around GLP-1 medications• Building a sustainable active lifestyle• Appreciating yourself at every stage of the journeyLinks Mentioned:Your Level Fitness:https://yourlevelfitness.comJournal Prompts:https://yourlevelfitness.com/emailEmail Daryl:daryl@yourlevelfitness.comThank you for listening to Life During and After GLP-1.My goal isn't to tell you what your journey should look like. My goal is to encourage you to think about the lifestyle you're building, the trade-offs you're making, and the version of normal you ultimately want for yourself. The more intentional you are about those decisions, the more likely you are to create a lifestyle you'll actually want to maintain for the long term.

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. A new GLP-1 has entered the chat, and I'm already seeing a lot of confusion around it. Meet Foundayo (orforglipron), a needle-free tablet you take once a day with none of the usual restrictions around timing, food, or storage.On paper, it sounds like the easier option. And for some people, it might be. But like most things in this space, the headline only tells part of the story.In this episode, I'm breaking down what you really need to know before considering it, from cost and access to drug interactions and what the latest trial data shows about maintenance.ReferencesEp. 156. Oral Wegovy: How to Take It, Who It's For, and What It Costs with Joseph Zucchi, PASecure your spot for the September round of The 30/30 Program now (spaces limited).Get the free podcast roadmap for The Obesity GuideSubscribe to my Youtube channelAll of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Is retatrutide, the new triple agonist GLP-1, the next big thing in weight loss (or even rapid fat loss)?That depends on how the drug works, what the results are, the reality between the headlines and the evidence, and what happens to your weight when you stop.This episode breaks down retatrutide, the GLP-1, GIP, and glucagon triple agonist behind the largest weight loss numbers ever recorded in this class. It covers the Phase 2 obesity trial and the Phase 3 Triumph results, plus why cross-trial comparisons to semaglutide and tirzepatide deserve skepticism.We examine the body composition data (or lack thereof), and why a bigger number on the scale just amplifies the stakes for muscle mass, weight regain, and the off-ramp. Especially relevant for adults over 40 who are taking, considering, or planning to come off a GLP-1.Enroll in Eat More Lift Heavy, the 26-week coached program where adults over 40 build the nutrition and training skills to preserve muscle, lose fat, and manage their physique for life, including support for lifestyle changes needed while taking GLP-1s (and to come off them if desired).Timestamps:0:00 - Retatrutide and the biggest question for GLP-1 users 3:08 - How this new triple agonist works 4:46 - Phase 2 and Phase 3 weight loss numbers 5:38 - Cross-trial comparisons and their limits 6:23 - Fat, muscle, and what the trial did NOT measure 8:30 - Strength training over 40 and accelerated muscle loss 10:07 - Building the lifestyle (alongside using the drug) 14:10 - Resistance training and protein 16:00 - Rate of loss on a powerful drug like retatrutide 17:30 - The off-ramp when you stop 18:23 - Weight regain and body fat overshooting 22:03 - Retatrutide access and the gray market 24:11 - Bonus: 3-question test to keep your resultsEpisode Mentioned:Sometimes More Is More (The Sedentary Lifter Problem)

Resources for the Community:___________________________________________________________________Linktree Our Favorite ThingsNeed help appealing your GLP-1 denials? www.FindHonestCare.com/KimRo - Telehealth for GLP1 Weight ManagementGLP-1 Stall? Why Your Body Stops Losing Weight | Dr. Michelle GordonHosts Kim Carlos and Kat Carter talk with obesity medicine specialist Dr. Michelle Gordon about the biological factors behind a GLP-1 weight loss plateau. If you are on a medication like tirzepatide or semaglutide and the scale stops moving, it is driven by a complex neuroendocrine response.Dr. Gordon explains that the hypothalamus operates like a stubborn thermostat, defending a specific weight set point. When you lose weight, the brain reads the change as a threat and triggers physiological defenses. To prevent further weight loss, the body increases hunger hormones and simultaneously lowers its energy expenditure.Key topics include:The Mechanism of a Stall: A weight plateau occurs at the exact point where your declining daily energy expenditure meets your rising natural hunger signals.Menopause and Fat Oxidation: Midlife hormonal shifts cause fat oxidation to drop, which alters metabolic burn rates and shifts fat storage to the stomach.The Chronic Disease Reality: Clinical data shows that stopping a GLP-1 medication typically results in regaining about two thirds of the lost weight, proving obesity requires continuous management.Muscle Mass Preservation: Rapid weight loss from any method causes muscle loss, making strength training essential to preserve lean muscle and protect long-term functional health.Connect to Dr. Michelle Gordon:Substack: https://drmichellegordon.substack.com/Instagram: https://www.instagram.com/doctormichellegordon/Facebook: https://www.facebook.com/drmichellegordon/Practice Website: https://drmichellegordon.com/LinkedIn: https://www.linkedin.com/in/drmichellegordon/______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Discover why hormones are off and what's really driving the imbalance. In this episode, we break down five root causes — from gut dysfunction and disrupted sleep to chronic stress, appetite dysregulation, and omega-3 deficiency — and walk through what you can actually do to fix it. FEATURED PRODUCT Berberine is a powerful botanical compound that acts as a natural GLP-1 supporter — the same metabolic pathway targeted by medications like Ozempic — helping regulate blood sugar, reduce insulin resistance, and restore appetite signaling from the gut. Since metabolic hormones like insulin and leptin are the first to derail your entire hormone cascade, Berberine directly addresses one of the deepest root causes discussed in this episode. It also supports gut microbiome diversity, making it a foundational tool for anyone working to reclaim hormonal balance naturally.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What if the reason so many people struggle on GLP-1 medications isn't the medication itself — but the way it's being dosed?Today we're diving into something that could genuinely change the way you think about GLP-1 therapy: custom dosing. And there is honestly no one better to talk about this with than Dr. Ian Justl Ellis.Dr. Ian is a board-certified physician, certified personal fitness instructor, and the creator of the MyLevel GLP-1 Precision Dosing Engine. He's also the founder and CEO of VOA Fit, where he provides highly personalized concierge care through advanced GLP-1 therapy, hormone optimization, and peptide protocols — all paired with real-world fitness and nutrition strategies. Before transitioning into obesity medicine, he spent a decade in emergency medicine.What makes his perspective especially valuable is how he bridges clinical expertise with lived experience in weight management. His work doesn't just focus on prescribing GLP-1s, but on optimizing how they're actually used in real-world patients. And that's exactly what this conversation is about — how dosing strategy can completely change outcomes.Topics discussed:Why GLP-1 results may depend more on dosing than the medication itselfDr. Ian's early belief in discipline — and why it eventually broke downWhen personal struggle turned into a medical reframe of obesityThe first experience with GLP-1s and the reality behind the resultsWhy “dose” isn't the full story — understanding GLP-1 drug levelsMoving from standard protocols to individualized GLP-1 levelingHow personalized GLP-1 dosing works in real patientsThe future of GLP-1 therapy: a more responsive, guided model of careRethinking weight loss: from fixed doses to adaptive biologyThere's a lot more nuance to GLP-1 therapy than standard protocols tend to show, and this episode really breaks down what happens when dosing becomes personalized rather than fixed.So if you want to understand how this approach actually works in practice — and why it might completely shift how we think about weight management — tune in to the full episode.Connect with Dr. Ian:Website: voafit.com,Instagram: voafitmdLearn about MyLevel:  voafit.com/mylevelBook a Consult: go.voafit.comMeet Our Clinic: voafit.comConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

How do we navigate health information when we are constantly flooded with opinions, studies, social media advice, expert voices, and "evidence-based" claims? As a family medicine and obesity medicine physician, Dr. Emily vulnerably shares the tension she personally feels between trusting evidence, honoring expert perspective, and learning how to listen to your own body. This episode is not about rejecting science. It's not about ignoring experts. And it's not about "Dr. Google" becoming your primary care provider. It's about slowing down long enough to recognize that health is often more nuanced than one headline, one influencer, one study, or one viral opinion online. Dr. Emily walks through real-life examples involving GLP-1 medications, dementia research, medication side effects, social media health trends, and even her own recent unexplained health journey with severe eye swelling and allergic reactions. Throughout the episode, she explores: The difference between evidence-based medicine and expert interpretation Why studies don't always tell the full story The dangers of oversimplified health advice online How social media algorithms can distort medical conversations Why your body's lived experience matters The importance of slowing down and asking better questions How fear can push us into desperate health decisions The role that prayer, wisdom, discernment, and self-awareness play in healing Dr. Emily also opens up personally about: Navigating ongoing health symptoms without easy answers Working with multiple specialists Learning to trust both medical expertise and body awareness Why she values primary care medicine so deeply The emotional weight of making health decisions in a world full of noise This episode feels less like a lecture and more like sitting down with someone who genuinely wants you to pause, breathe, think critically, and remember that your health journey deserves wisdom — not panic. Because sometimes the healthiest thing you can do is stop searching for instant answers long enough to actually listen. Your body may need to become the expert first before the internet does. Ready for more guidance and support? Head to www.emilyvinzantmd.com or follow Dr. Emily on Facebook and Instagram for more science-backed common-sense health.  

Lisa Levy Shaub '91 joins us for a conversation about reinvention, resilience, and finding your true calling.She shares behind-the-scenes stories about working with Oprah, the lessons she learned about behavior change, confidence, and wellness, and why she believes some of life's biggest pivots can become our greatest opportunities.We also discuss midlife health, longevity, GLP-1 medications, community, and how to build a healthier, more meaningful next chapter.Connect with Lisa:Instagram: @Lisa_nyc_coachWebsite: apositivepractice.comNot sponsored by or affiliated with Cornell University 

The top ten grossing movies of 2025 include four sequels, two reboots, and two live-action remakes. The only film with a genuinely original premise is Sinners. Brian From turns that observation into a deeper question: why is an entire generation — raised online, drowning in new content — desperately reaching backward toward Polaroid cameras, record players, VHS tapes, and music from eras they never lived? Kyle Burks at the Gospel Coalition says Gen Z is drunk on nostalgia, and Brian argues it's not just Gen Z. That longing for something simpler, something that lasts, something you can hold onto — it's not ultimately a longing for the past. It's a longing for the eternal. Then: celebrating as a spiritual discipline — why moving on too quickly to the next thing robs us of joy, and what Brian learned hosting his son's graduation party. The Knicks win their first championship in 53 years. A pastor's thread of ordinary life-change stories from his congregation that reads like a modern Acts 8. GLP-1 drugs and Christians — less a right-or-wrong question and more an identity question. And a top-ten list of 2000s worship songs that will immediately transport you back to every lock-in you ever attended.See omnystudio.com/listener for privacy information.

GLP-1s are often talked about as appetite suppressants.But I think that's only part of the story.Because for some people, these medications aren't suppressing an appetite at all—they're helping regulate an appetite that feels completely out of control.But for other people?They may be doing something very different.In this episode, I'm talking about the difference between appetite regulation and appetite suppression, why that distinction matters, and what it means for how we think about hunger, food noise, weight loss, and health.I get into:Why appetite regulation and appetite suppression aren't the same thingThe role food noise does (and doesn't) play in all of thisWhy your experience on a GLP-1 might be very different from someone else'sThe potential downside of having too little appetiteThe questions I think we should all be asking when it comes to these medicationsThis is one of those episodes that got me thinking long after I stopped recording—and I know it'll get you thinking too.One of the articles I referencedConnect with JordanaFind me on InstagramSign up for my weekly letter with personal stories and nutrition, body image and mindset tipsSchedule a free discovery call to talk more about working together Listen to more episodes of The Diet Diaries

In this episode the guys break down how to eat carbs for muscle gains and fat loss — why they're not essential but are beneficial, how to figure out if you do better higher carb or lower fat, timing carbs around workouts, choosing easy-digesting sources, and why drinking carbs is almost always a mistake. They also get into a deep dive on PDE5 inhibitors (Viagra/Cialis) and the emerging data showing 30–40% reduction in all-cause cardiovascular mortality, potential neuroprotective and anti-cancer effects, and why Sal thinks they'll be recommended to most men over 40 within a decade. Plus: side bends as a highly underrated QL exercise, the Guy Ritchie movie "In the Gray," Sal's son's gem hustle, Adam's commercial-grade mosquito killer, Google releasing 32 million lab-bred mosquitoes into California, pirates and their eye patches, cauliflower ear plastic surgery in Russia, and giant tree spiders in Malaysia. Then they coach live callers submitted through mplivecaller.com — Jesse from Florida on reverse dieting after a bad coach left her overtrained and underfed, Augie from Alabama on combining MAPS PPL with running for fall race prep, Kaylene from New York on sobriety from THC and getting comfortable bulking, and Vanessa from the UK on building her glutes while letting go of the step and scale obsession. MAPS Summer Sale — https://mapsfitnessproducts.com Code: SUMMER40 — 40% off everything — June 1–14 only Mind Pump Fitness Coaching — https://mindpumpfitnesscoaching.com 1.9 NASM CEUs SPONSORS Crisp Power (protein pretzels) — https://www.crisppower.com/mindpump Code: MINDPUMP — 10% off. Up to 28g protein, 15g carbs, baked not fried, zero added sugar, vegan, GLP-1 friendly. New 7.1oz variety pack bundles now available. Joovv (red light therapy) — https://joovv.com/mindpump Code: MINDPUMP — $50 off first purchase. Discussed on air for stretch marks and skin health. Seed Daily Synbiotic — https://seed.com/mindpump Code: 25MINDPUMP — 25% off first month LINKS Submit a live caller question: https://mplivecaller.com Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia 0:00 - Intro 2:07 - How to eat carbs for muscle gains and fat loss — the full breakdown 17:29 - Bookending workouts with carbs & choosing easy-digesting sources 23:42 - PDE5 inhibitors (Viagra/Cialis) — 30–40% cardiovascular mortality reduction & longevity data 33:41 - Side bends for the QL — the most underrated exercise nobody does 39:32 - Sal's son's gem hustle, World Vision kids & the Lego birthday revelation 47:08 - Adam's commercial mosquito killer, Google releasing 32M lab mosquitoes & laser bug defense 1:08:29 - Caller: Jesse (Florida) — overtrained, underfed by bad coach, incredibly strong, gets a coach 1:17:53 - Caller: Augie (Alabama) — combining MAPS PPL with running for fall races 1:22:23 - Caller: Kaylene (New York) — THC sobriety, cannabinoid hyperemesis, bulking comfort 1:39:16 - Caller: Vanessa (UK) — building glutes, letting go of steps and scale, needs to gain weight